Copyright Reports & Markets. All rights reserved.

Global GLP-1 Agonist Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope of GLP-1 Agonist
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global GLP-1 Agonist Consumption Value by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Long-Acting Drug
    • 1.3.3 Short-Acting Drug
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global GLP-1 Agonist Consumption Value by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Diabetes
    • 1.4.3 Obesity
    • 1.4.4 Nonalcoholic Fatty Liver Disease
    • 1.4.5 Metabolic Disorder
    • 1.4.6 Alzheimer's Disease
    • 1.4.7 Other
  • 1.5 Global GLP-1 Agonist Market Size & Forecast
    • 1.5.1 Global GLP-1 Agonist Consumption Value (2018 & 2022 & 2029)
    • 1.5.2 Global GLP-1 Agonist Sales Quantity (2018-2029)
    • 1.5.3 Global GLP-1 Agonist Average Price (2018-2029)

2 Manufacturers Profiles

  • 2.1 Novo Nordisk
    • 2.1.1 Novo Nordisk Details
    • 2.1.2 Novo Nordisk Major Business
    • 2.1.3 Novo Nordisk GLP-1 Agonist Product and Services
    • 2.1.4 Novo Nordisk GLP-1 Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 Novo Nordisk Recent Developments/Updates
  • 2.2 AstraZeneca
    • 2.2.1 AstraZeneca Details
    • 2.2.2 AstraZeneca Major Business
    • 2.2.3 AstraZeneca GLP-1 Agonist Product and Services
    • 2.2.4 AstraZeneca GLP-1 Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 AstraZeneca Recent Developments/Updates
  • 2.3 Sanofi
    • 2.3.1 Sanofi Details
    • 2.3.2 Sanofi Major Business
    • 2.3.3 Sanofi GLP-1 Agonist Product and Services
    • 2.3.4 Sanofi GLP-1 Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 Sanofi Recent Developments/Updates
  • 2.4 GSK
    • 2.4.1 GSK Details
    • 2.4.2 GSK Major Business
    • 2.4.3 GSK GLP-1 Agonist Product and Services
    • 2.4.4 GSK GLP-1 Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 GSK Recent Developments/Updates
  • 2.5 Eli Lilly
    • 2.5.1 Eli Lilly Details
    • 2.5.2 Eli Lilly Major Business
    • 2.5.3 Eli Lilly GLP-1 Agonist Product and Services
    • 2.5.4 Eli Lilly GLP-1 Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 Eli Lilly Recent Developments/Updates
  • 2.6 Zealand Pharma A/S
    • 2.6.1 Zealand Pharma A/S Details
    • 2.6.2 Zealand Pharma A/S Major Business
    • 2.6.3 Zealand Pharma A/S GLP-1 Agonist Product and Services
    • 2.6.4 Zealand Pharma A/S GLP-1 Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 Zealand Pharma A/S Recent Developments/Updates
  • 2.7 hansoh
    • 2.7.1 hansoh Details
    • 2.7.2 hansoh Major Business
    • 2.7.3 hansoh GLP-1 Agonist Product and Services
    • 2.7.4 hansoh GLP-1 Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 hansoh Recent Developments/Updates
  • 2.8 BENEMAE
    • 2.8.1 BENEMAE Details
    • 2.8.2 BENEMAE Major Business
    • 2.8.3 BENEMAE GLP-1 Agonist Product and Services
    • 2.8.4 BENEMAE GLP-1 Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 BENEMAE Recent Developments/Updates

3 Competitive Environment: GLP-1 Agonist by Manufacturer

  • 3.1 Global GLP-1 Agonist Sales Quantity by Manufacturer (2018-2023)
  • 3.2 Global GLP-1 Agonist Revenue by Manufacturer (2018-2023)
  • 3.3 Global GLP-1 Agonist Average Price by Manufacturer (2018-2023)
  • 3.4 Market Share Analysis (2022)
    • 3.4.1 Producer Shipments of GLP-1 Agonist by Manufacturer Revenue ($MM) and Market Share (%): 2022
    • 3.4.2 Top 3 GLP-1 Agonist Manufacturer Market Share in 2022
    • 3.4.2 Top 6 GLP-1 Agonist Manufacturer Market Share in 2022
  • 3.5 GLP-1 Agonist Market: Overall Company Footprint Analysis
    • 3.5.1 GLP-1 Agonist Market: Region Footprint
    • 3.5.2 GLP-1 Agonist Market: Company Product Type Footprint
    • 3.5.3 GLP-1 Agonist Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global GLP-1 Agonist Market Size by Region
    • 4.1.1 Global GLP-1 Agonist Sales Quantity by Region (2018-2029)
    • 4.1.2 Global GLP-1 Agonist Consumption Value by Region (2018-2029)
    • 4.1.3 Global GLP-1 Agonist Average Price by Region (2018-2029)
  • 4.2 North America GLP-1 Agonist Consumption Value (2018-2029)
  • 4.3 Europe GLP-1 Agonist Consumption Value (2018-2029)
  • 4.4 Asia-Pacific GLP-1 Agonist Consumption Value (2018-2029)
  • 4.5 South America GLP-1 Agonist Consumption Value (2018-2029)
  • 4.6 Middle East and Africa GLP-1 Agonist Consumption Value (2018-2029)

5 Market Segment by Type

  • 5.1 Global GLP-1 Agonist Sales Quantity by Type (2018-2029)
  • 5.2 Global GLP-1 Agonist Consumption Value by Type (2018-2029)
  • 5.3 Global GLP-1 Agonist Average Price by Type (2018-2029)

6 Market Segment by Application

  • 6.1 Global GLP-1 Agonist Sales Quantity by Application (2018-2029)
  • 6.2 Global GLP-1 Agonist Consumption Value by Application (2018-2029)
  • 6.3 Global GLP-1 Agonist Average Price by Application (2018-2029)

7 North America

  • 7.1 North America GLP-1 Agonist Sales Quantity by Type (2018-2029)
  • 7.2 North America GLP-1 Agonist Sales Quantity by Application (2018-2029)
  • 7.3 North America GLP-1 Agonist Market Size by Country
    • 7.3.1 North America GLP-1 Agonist Sales Quantity by Country (2018-2029)
    • 7.3.2 North America GLP-1 Agonist Consumption Value by Country (2018-2029)
    • 7.3.3 United States Market Size and Forecast (2018-2029)
    • 7.3.4 Canada Market Size and Forecast (2018-2029)
    • 7.3.5 Mexico Market Size and Forecast (2018-2029)

8 Europe

  • 8.1 Europe GLP-1 Agonist Sales Quantity by Type (2018-2029)
  • 8.2 Europe GLP-1 Agonist Sales Quantity by Application (2018-2029)
  • 8.3 Europe GLP-1 Agonist Market Size by Country
    • 8.3.1 Europe GLP-1 Agonist Sales Quantity by Country (2018-2029)
    • 8.3.2 Europe GLP-1 Agonist Consumption Value by Country (2018-2029)
    • 8.3.3 Germany Market Size and Forecast (2018-2029)
    • 8.3.4 France Market Size and Forecast (2018-2029)
    • 8.3.5 United Kingdom Market Size and Forecast (2018-2029)
    • 8.3.6 Russia Market Size and Forecast (2018-2029)
    • 8.3.7 Italy Market Size and Forecast (2018-2029)

9 Asia-Pacific

  • 9.1 Asia-Pacific GLP-1 Agonist Sales Quantity by Type (2018-2029)
  • 9.2 Asia-Pacific GLP-1 Agonist Sales Quantity by Application (2018-2029)
  • 9.3 Asia-Pacific GLP-1 Agonist Market Size by Region
    • 9.3.1 Asia-Pacific GLP-1 Agonist Sales Quantity by Region (2018-2029)
    • 9.3.2 Asia-Pacific GLP-1 Agonist Consumption Value by Region (2018-2029)
    • 9.3.3 China Market Size and Forecast (2018-2029)
    • 9.3.4 Japan Market Size and Forecast (2018-2029)
    • 9.3.5 Korea Market Size and Forecast (2018-2029)
    • 9.3.6 India Market Size and Forecast (2018-2029)
    • 9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
    • 9.3.8 Australia Market Size and Forecast (2018-2029)

10 South America

  • 10.1 South America GLP-1 Agonist Sales Quantity by Type (2018-2029)
  • 10.2 South America GLP-1 Agonist Sales Quantity by Application (2018-2029)
  • 10.3 South America GLP-1 Agonist Market Size by Country
    • 10.3.1 South America GLP-1 Agonist Sales Quantity by Country (2018-2029)
    • 10.3.2 South America GLP-1 Agonist Consumption Value by Country (2018-2029)
    • 10.3.3 Brazil Market Size and Forecast (2018-2029)
    • 10.3.4 Argentina Market Size and Forecast (2018-2029)

11 Middle East & Africa

  • 11.1 Middle East & Africa GLP-1 Agonist Sales Quantity by Type (2018-2029)
  • 11.2 Middle East & Africa GLP-1 Agonist Sales Quantity by Application (2018-2029)
  • 11.3 Middle East & Africa GLP-1 Agonist Market Size by Country
    • 11.3.1 Middle East & Africa GLP-1 Agonist Sales Quantity by Country (2018-2029)
    • 11.3.2 Middle East & Africa GLP-1 Agonist Consumption Value by Country (2018-2029)
    • 11.3.3 Turkey Market Size and Forecast (2018-2029)
    • 11.3.4 Egypt Market Size and Forecast (2018-2029)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
    • 11.3.6 South Africa Market Size and Forecast (2018-2029)

12 Market Dynamics

  • 12.1 GLP-1 Agonist Market Drivers
  • 12.2 GLP-1 Agonist Market Restraints
  • 12.3 GLP-1 Agonist Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry
  • 12.5 Influence of COVID-19 and Russia-Ukraine War
    • 12.5.1 Influence of COVID-19
    • 12.5.2 Influence of Russia-Ukraine War

13 Raw Material and Industry Chain

  • 13.1 Raw Material of GLP-1 Agonist and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of GLP-1 Agonist
  • 13.3 GLP-1 Agonist Production Process
  • 13.4 GLP-1 Agonist Industrial Chain

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 GLP-1 Agonist Typical Distributors
  • 14.3 GLP-1 Agonist Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global GLP-1 Agonist market size was valued at USD 21200 million in 2022 and is forecast to a readjusted size of USD 59500 million by 2029 with a CAGR of 15.9% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
    GLP-1 is a polypeptide hormone secreted by the intestine after being stimulated by food. It can stimulate the pancreatic beta cells to secrete insulin and participate in the regulation of blood sugar balance in the human body. However, natural GLP-1 is easily degraded by dipeptidyl peptidase in vivo and loses its activity. In order to make GLP-1 better for clinical application, drug developers have modified its structure and developed a series of GLP-1 receptor agonists. GLP-1 receptor agonists can exert the same biological effects as natural GLP-1, and can also avoid being degraded and inactivated, thereby prolonging the action time.
    This report is a detailed and comprehensive analysis for global GLP-1 Agonist market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
    Key Features:
    Global GLP-1 Agonist market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
    Global GLP-1 Agonist market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
    Global GLP-1 Agonist market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
    Global GLP-1 Agonist market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for GLP-1 Agonist
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global GLP-1 Agonist market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, AstraZeneca, Sanofi, GSK and Eli Lilly, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
    Market Segmentation
    GLP-1 Agonist market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Long-Acting Drug
    Short-Acting Drug
    Market segment by Application
    Diabetes
    Obesity
    Nonalcoholic Fatty Liver Disease
    Metabolic Disorder
    Alzheimer's Disease
    Other
    Major players covered
    Novo Nordisk
    AstraZeneca
    Sanofi
    GSK
    Eli Lilly
    Zealand Pharma A/S
    hansoh
    BENEMAE
    Market segment by region, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe GLP-1 Agonist product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of GLP-1 Agonist, with price, sales, revenue and global market share of GLP-1 Agonist from 2018 to 2023.
    Chapter 3, the GLP-1 Agonist competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the GLP-1 Agonist breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
    Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and GLP-1 Agonist market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
    Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
    Chapter 13, the key raw materials and key suppliers, and industry chain of GLP-1 Agonist.
    Chapter 14 and 15, to describe GLP-1 Agonist sales channel, distributors, customers, research findings and conclusion.

    Buy now